Schizophrenia Clinical Trial
— Metamemory 2Official title:
Evaluation of Metamemory Using a Semantic Construction Strategy in Patients With Schizophrenia
The purpose of this study is to determine the respective roles of aging and schizophrenia in
the regulation of metamemory using a sentence construction strategy. 4 groups will be
necessary to comparison:
Adult patients (18-45 years) Adult controls (18-45 years) Aged patients (≥ 55 years) Aged
controls (≥ 55 years)
The effects of age and the disease could lead to interaction in regulating metamemory. The
effect of age would be aggravated by the disease.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | September 2020 |
Est. primary completion date | February 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - For both: - MMSE score greater than or equal to, - 22 if no grade - 23 if study certificate or CAP or college without patent - 25 if patent or school without the tray - 26 or more when bin - IQ = 75 (fNART) - Age: between 18 and 45 years for adults, and 55 and older for older, For patients : - DSM-5 criteria of schizophrenia - Adult patients (<45 years) will be matched to elderly patients (> 55 years) gender and IQ, - Patients followed as outpatients, - Age of onset of the disease less than 40 years, - Patients whose disease has stabilized: no changes psychotropic treatment for at least 1 month - Not more of a benzodiazepine, - Patients on protection of justice or not, For controls : - - Matched for sex to patient - Age-matched (+/- 3 years) to patient - Matched for IQ (score fNART +/- 10%) to patients Exclusion Criteria: - For patients : - Any other comorbid psychiatric diagnosis of Axis I DSM-5 - Extrapyramidal syndrome or tardive dyskinesia (AIMS score <2 BARS score <2 and score Simpson and Angus <3) - Calgary depression scale = 6 - Current or past addiction to all toxic substances (including alcohol and cannabis) except tobacco. - Current or past use of all toxic consumption (excluding alcohol, tobacco and cannabis). - Use of alcohol or cannabis before the age of 15 years - Alcohol abuse in the past 6 months. - Cannabis abuse in the past 6 months and cannabis use in the last 3 months. - Patients with impaired vision or hearing preventing the realization of the tests. For controls: - Any psychiatric diagnosis according to DSM-5, including addictions (excluding tobacco) - Score HADS Anxiety = 8 and Depression = 8 - SCL90R: global severity score GSI> 0.33 for women and> 0.27 for men, or score diversity PST symptoms> 18.49 for men and> 21.97 for women or score of degree of discomfort PSDI> 1.27 for men and> 1.3 for women, scoring in the subscale Psychotic Features> 0. - Presence of a personality disorder at PDQ4 + - Head injuries, brain injuries or diseases, - vision or hearing problems preventing the realization of the tests. - Current or past addiction to all toxic substances (including alcohol and cannabis) except tobacco. - Current or past use of all toxic consumption (excluding alcohol, tobacco and cannabis). - Long-term Anticholinergic treatment. - Related to the first degree diagnosed with a psychotic disorder |
Country | Name | City | State |
---|---|---|---|
France | CHU Clermont-Ferrand | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | LAPSCO, Psychology University, Blaise Pascal University, Clermont-Ferrand. |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) in the sentence construction strategy | the 4 groups of participants formed by the case-control study in two age strata value their judgments of learning for each pair of words using a 5 point scale (0%, 25%, 50%, 75%, 100%) in the sentence construction strategy. Four groups are : Adult schizophrenic patients (18-45 years) Aged patients with schizophrenia (= 55 years) Adults controls (18-45 years) Aged controls (= 55 years) |
at day 1 | |
Secondary | difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) between sentence construction and reading strategies. | the 4 groups of participants formed by the case-control study in two age strata, value their judgments of learning for each pair of words using a 5 point scale (0%, 25%, 50%, 75%, 100%) in a sentence construction strategy and in a reading strategy. For each group, difference between these two strategies will be compared. Four groups are : Adult schizophrenic patients (18-45 years) Aged patients with schizophrenia (= 55 years) Adults controls (18-45 years) Aged controls (= 55 years) |
at day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |